Overview

Open Label Extension Study in Patients With Idiopathic Pulmonary Fibrosis Who Completed Protocol AC-052-321/ BUILD 3 / NCT00391443

Status:
Completed

Trial end date:
2010-05-01

Target enrollment:

Participant gender:

Summary

This Open-label extension study in patients with Idiopathic Pulmonary Fibrosis who completed protocol AC-052-321 / BUILD 3 (NCT00391443) will asses the long term safety and tolerability of bosentan in patients with idiopathic pulmonary fibrosis (IPF).

Phase:

Phase 3

Details

Lead Sponsor:

Actelion

Treatments:

Bosentan